Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
1998-01-21
2002-12-17
Celsa, Bennett (Department: 1627)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S557000, C514S578000, C514S825000, C514S886000, C514S019300
Reexamination Certificate
active
06495514
ABSTRACT:
BACKGROUND OF THE INVENTION
1. Field of the Invention
The invention relates to a method for reducing inflammation and a method for inducing an analgesic effect in a subject and compounds thereof
2. Background Art
Inflammatory disease represents a pressing public health problem in our society. While rheumatoid arthritis is probably the most widely known chronic inflammatory disease, other examples are ulcerative colitis, Crohn's disease, gout, bursitis and tendinitis. Traditionally, inflammation has been treated with aspirin-like drugs, steroid based compounds, or non-steroidal anti-inflammatory drugs. These drugs are of variable effectiveness; however, they are not therapeutic in nature.
Neuropeptides are released from peripheral terminals of primary afferent sensory nerves and contribute significantly to the inflammatory response of a variety of diseases including rheumatoid arthritis. Examples of neuropeptides that have been investigated extensively are substance P (SP) and Calcitonin Gene-Related Peptide (CGRP). These neuropeptides have been shown to be capable of producing vasodilation, increasing vascular permeability, attracting and activating phagocytic white blood cells, releasing cytokines, lysosomal enzymes and prostaglandins from these cells, increasing the expression of adhesion molecules as well as causing the activation of synoviocytes.
Several pharmacological approaches to reduce the neurogenic component of inflammation have been evaluated; however, a means for reducing inflammation by reducing the release of a. neuropeptide responsible for inflammation has not been developed.
Thus, there remains a need in the art for reducing inflammation in a subject. Applicants have discovered such a method, and have also discovered a method for inducing an analgesic effect in a subject. The prior art does not disclose the methods or compounds such as those described and claimed herein.
SUMMARY OF THE INVENTION
In accordance with the purpose(s) of this invention, as embodied and broadly described herein, this invention, in one aspect, relates to a method for reducing inflammation in a subject, comprising administering to the subject an effective amount of the compound having the structure I or II:
wherein,
R
1
is C
1
-C
10
branched or straight chain alkyl, aryl, an amino acid, or a peptide; and
R
2
is hydrogen or lower C
1
-C
5
branched or straight alkyl,
or the salt or ester thereof, wherein
the stereochemistry about the carbon-carbon double bond is trans.
The invention further relates to a method for inducing an analgesic effect in a subject, comprising administering to the subject an effective amount of the compound having the structure I or II:
wherein,
R
1
is C
1
-C
10
branched or straight chain alkyl, aryl, an amino acid, or a peptide, and
R
2
is hydrogen or lower C
1
-C
5
branched or straight alkyl,
or the salt or ester thereof, wherein
the stereochemistry about the carbon-carbon double bond is trans.
The invention further provides a compound for reducing inflammation and/or inducing an analgesic effect having the structure II:
wherein, R
1
is an N-acyl amino acid or peptide,
or the salt or ester thereof.
Additional advantages of the invention will be set forth in part in the description which follows, and in part will be obvious from the description, or may be learned by practice of the invention. The advantages of the invention will be realized and attained by means of the elements and combinations particularly pointed out in the appended claims. It is to be understood that both the foregoing general description and the following detailed description are exemplary and explanatory only and are not restrictive of the invention, as claimed.
REFERENCES:
Ogonowski et al., FASEB J. vol. 9, No. 4 p. A956, Apr. 1995.*
Bundgaard, Design of Prodrugs (Elsevier Publishing) Ch. 1 pp. 1-10, 1985.*
Matucci-Cerinice et al.: “The Contribution of the peripheral nervous system and the neuropeptide network to the development of synovial inflammation.” Clinical and Experimental Rheumatology 10:pp. 211-215, 1992.
Panagakos et al.“Modulation of Carrageenan-Induced Hind Paw Edema by Substance P.” Inflammation. vol. 18. No. 3, pp 285-292, 1994.
Bradbury, A.F., Finnie, M.D.A. and Smyth, D.G.: Mechanism of C-terminal amide formation by pituitary enzymes. Nature 298: 686-688, 1982.
Colpaert, F.C., Donner, J. and Lembeck, F.: Effects of capsaicin on inflammation and on the substance P content of nervous tissue in rate with adjuvant arthritis. Life Sci. 32: 1827-1834, 1983.
Cronstein, B.N. and Weissmann, G.: Targets for antiinflammatory drugs. Annu. Rev. Pharmacol. Toxicol. 35: 449-462, 1995.
DiRosa, M., Giroud, J.P. and Willoughby, D.A.: Studies of the mediators of the acute inflammatory response induced in rats in different sites by carrageenan and turpentine. J. Pathol 104: 15-29, 1971.
Doherty, N.S., Beaver, T.H., Chan, K.Y., Coutant, J.E. and Westrich, G.L.: The role of prostaglandins in the nociceptive response induced by intraperitoneal injection of zymosan in mice. Br. J. Pharmacol. 91: 39-47, 1987.
Dray, A. and Perkins, M.: Bradykinin and inflammatory pain. Trends Neurosci. 61: 99-104, 1993.
Gamse, R.: Capsaicin and nociception in the rat and mouse. Possible role of substance. P. Naunyn-Schmiedeberg Arch. Pharmacol. 320: 205-216, 1982, p206.
Garry, M.G. and Hargreaves, K.M.: Enhanced release of immunoreactive CGRP and substance P from spinal dorsal horn slices occurs during carrageenan inflammation. Brain Res. 582: 139-142, 1992.
Iadarola, M.J. and Draisci, G.: Elevation of spinal cord dynorphin mRNA compared to dorsal root ganglion peptide mRNAs during peripheral inflammation. In The Arthritic Rat as a Model of Clinical Pain? ed. by J.M. Beeson and G. Guilbaud, pp. 173-183, Elsevier, Armsterdam, 1988.
Katopodis, A.G. and May, S.W.: Novel substrates and inhibitors of peptidylglycine &agr;-amidating monooxygenase. Biochemistry 29: 4541-4548, 1990.
Katopodis, A.G., Ping, D. and May, S.W.: A Novel enzyme from bovine neurointermediate pituitary catalyzes dealkylation of &agr;-hydroxyglycine derivatives, thereby functioning sequentially with peptidylglycine &agr;-amidating monooxygenase in peptide amidation. Biochemistry 29: 6115-6120, 1990.
Katopodis, A.G., Ping, D., Smith C.E. and May, S.W.: Functional and structural characterization of peptidylamidogylocate lyase, the enzyme catalyzing the second step in peptide amidation. Biochemistry 30: 6189-6194, 1991.
Lam, F.Y. and Ferrell, W.R.: Neurogenic component of different models of acute inflammation in the rat knee joint. Ann. Rheum. Dis. 50: 747-751, 1991.
Levine, J.D., Clark, R., Devor, M., Helmes, C., Moskowitz, M.A. and Basbaum, A. I.: Intraneuronal substance P contributes to the severity of experimental arthritis. Science 226: 547-549, 1984.
Li, C., Oldham, C.D. and May, S.W., NN-Dimethyl-1,4-phenylenediamine as an alternative reductant for peptidylglycine &agr;-amidating mono-oxygenase catalysis. Biochem. J. 300: 31-36, 1994.
Oldham, C.D., Li, C., Girard, P.R., Nerem, R.M. and May, S.W.: Peptide amidating enzymes are present in cultured endothelian cells. Biochem. Biophys. Res. Commun. 184: 323-329, 1992.
Ping, D., Mounier, C.E. and May, S.W.: Reaction versus subsite stereospecificity of peptidyglycine &agr;-monooxygenase and peptidylamidoglycolate lyase, the two enzymes involved in peptide amidation. J. Biol. Chem. 270: 29250-29255, 1995.
Smith, G., Harrison, S., Bowers, J., Weisman, J. and Birch, P.: Non-specific effects of the tachykinin NK1receptor anatagonist, CP-99,994, in antinociceptive tests in rat, mouse and gerbil. Eur. J. Pharmacol. 271: 481-487: 1994.
Tissot, M., Pradelles, P. and Giroud, J.P.: Substance-P-like levels in inflammatory exudates. Inflammation 12: 25-35, 1988.
Vinegar, R., Truax, J.F., Selph, J.L., Johnston, P.R., Venable, A.L. and McKenzie, K.K.: Pathway to carrageenan-induced inflammation in the hind limb of the rat. Fed. Proc. 46: 118-126, 1987.
Ogonowski, A.A., May, S.W., Moore, A.B., Barrett, L.T., O Bryant, C. L., Pollock, S.H.: Antiinflammatory and analgesic activity of an infib
May Sheldon W.
Pollock Stanley H.
Celsa Bennett
Mercer University
Needle & Rosenberg P.C.
LandOfFree
Method for reducing inflammation and inducing an analgesic... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for reducing inflammation and inducing an analgesic..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for reducing inflammation and inducing an analgesic... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2959502